This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (funded, already peer-reviewed, non-eHealth) (172)

Published on in Vol 5, No 3 (2016): Jul-Sept

Preventing Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome in High-Risk Patients: Protocol of a Randomized Placebo-Controlled Trial of Prednisone (PredART Trial)

Preventing Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome in High-Risk Patients: Protocol of a Randomized Placebo-Controlled Trial of Prednisone (PredART Trial)

Preventing Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome in High-Risk Patients: Protocol of a Randomized Placebo-Controlled Trial of Prednisone (PredART Trial)

Authors of this article:

Cari Stek1, 2, 3 Author Orcid Image ;   Charlotte Schutz1, 3 Author Orcid Image ;   Lisette Blumenthal1, 3 Author Orcid Image ;   Friedrich Thienemann1, 3 Author Orcid Image ;   Jozefien Buyze2 Author Orcid Image ;   Christiana Nöstlinger4 Author Orcid Image ;   Raffaella Ravinetto2 Author Orcid Image ;   Edwin Wouters5 Author Orcid Image ;   Robert Colebunders2 Author Orcid Image ;   Gary Maartens3 Author Orcid Image ;   Robert J Wilkinson1, 3, 6, 7 Author Orcid Image ;   Lutgarde Lynen2 Author Orcid Image ;   Graeme Meintjes1, 3 Author Orcid Image
Article Authors Cited by (9) Tweetations (2) Metrics

Journals

  1. Hurtado R, Meressa D, Goldfeld A. Treatment of drug-resistant tuberculosis among people living with HIV. Current Opinion in HIV and AIDS 2018;13(6):478 View
  2. Hammoud D, Boulougoura A, Papadakis G, Wang J, Dodd L, Rupert A, Higgins J, Roby G, Metzger D, Laidlaw E, Mican J, Pau A, Lage S, Wong C, Lisco A, Manion M, Sheikh V, Millo C, Sereti I. Increased Metabolic Activity on 18F-Fluorodeoxyglucose Positron Emission Tomography–Computed Tomography in Human Immunodeficiency Virus–Associated Immune Reconstitution Inflammatory Syndrome. Clinical Infectious Diseases 2019;68(2):229 View
  3. Meintjes G, Stek C, Blumenthal L, Thienemann F, Schutz C, Buyze J, Ravinetto R, van Loen H, Nair A, Jackson A, Colebunders R, Maartens G, Wilkinson R, Lynen L. Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS. New England Journal of Medicine 2018;379(20):1915 View
  4. Chelkeba L, Fekadu G, Tesfaye G, Belayneh F, Melaku T, Mekonnen Z. Effects of time of initiation of antiretroviral therapy in the treatment of patients with HIV/TB co-infection: A systemic review and meta-analysis. Annals of Medicine and Surgery 2020;55:148 View
  5. Church L, Chopra A, Judson M, Schlossberg D. Paradoxical Reactions and the Immune Reconstitution Inflammatory Syndrome. Microbiology Spectrum 2017;5(2) View
  6. Wouters E, Stek C, Swartz A, Buyze J, Schutz C, Thienemann F, Wilkinson R, Meintjes G, Lynen L, Nöstlinger C. Prednisone for the prevention of tuberculosis-associated IRIS (randomized controlled trial): Impact on the health-related quality of life. Frontiers in Psychology 2022;13 View
  7. Rapose A, Karande S. Tuberculosis, human immunodeficiency virus, and the immune reconstitution inflammatory syndrome. Journal of Postgraduate Medicine 2017;63(4):207 View
  8. Makarov P, Kravchenko I. Prognostic factors for immune reconstitution inflammatory syndrome in patients with HIV and tuberculosis during antiretroviral therapy. Vrach 2023:20 View

Books/Policy Documents

  1. Preston Church L, Chopra A, Judson M. Tuberculosis and Nontuberculous Mycobacterial Infections. View